AML treatment for older adults now focuses less on physical fitness and more on whether therapy can cure the disease while avoiding excessive strain. Medical professionals argue that the outdated distinction between “fit” and “unfit” patients no longer applies, as current treatments now extend across all patient profiles.
Dr. Zeidan explains that fitness determines whether chemotherapy can be administered, but not whether it remains the best option. In the case of a 72-year-old patient with NPM1-mutated AML, obesity, hypertension, and arthritis, he evaluates whether aggressive chemotherapy could induce remission without necessitating a transplant. If a transplant remains part of the plan, he recommends azacitidine combined with venetoclax as a preparatory treatment.
Most AML diagnoses occur in patients aged 68 or older, many of whom face multiple health issues alongside social barriers. A caregiver with disabilities or children living in another state can prevent travel for in-person treatment, even when outpatient options exist. Dr. Zeidan stresses that ongoing psychosocial evaluations are essential, particularly before transplant decisions, and advocates for teams that include social workers to guide treatment choices.
Age-related changes in disease biology lead to higher-risk classifications for older patients. Dr. Stein describes a 60-year-old woman with NPM1- and IDH1-mutated AML and obesity who underwent intensive chemotherapy. Her three-week ICU stay on a ventilator highlights concerns about whether azacitidine plus venetoclax followed by transplant might have been a safer alternative. He now advises clinicians to reassess the necessity of allogeneic stem cell transplants in similar cases.
Given the lack of perfect predictive tools, treatment decisions must depend on the evidence available at the time. Dr. Mahmoudjafari acknowledges the inherent uncertainty in these choices and emphasizes that clinicians should base their assessments on current knowledge rather than speculative outcomes.
Clinical trials remain critical in refining these strategies. Up next, in “Frailty, Comorbidity, and Social Determinants of Health in AML Treatment,” Dr. Murthy reviews practical frailty tools and Dr. Zeidan examines how social determinants of health shape treatment.